Aspirin's Impact on Heart Events in Diabetic Patients
Author Information
Author(s): Sonia Butalia, Alexander A. Leung, William A. Ghali, Doreen M. Rabi
Primary Institution: University of Calgary
Hypothesis
Does aspirin reduce the incidence of major adverse cardiovascular events in patients with diabetes mellitus?
Conclusion
Aspirin may reduce the risk of major adverse cardiovascular events in diabetic patients without cardiovascular disease, but it also increases the risk of bleeding complications.
Supporting Evidence
- Aspirin therapy led to a 9% relative reduction in major adverse cardiovascular events.
- For every 10,000 diabetic patients treated with aspirin, 109 major adverse cardiovascular events may be prevented.
- Patients with diabetes without cardiovascular disease may benefit from aspirin therapy, but also face increased bleeding risks.
Takeaway
Taking aspirin can help people with diabetes avoid serious heart problems, but it might also cause bleeding issues.
Methodology
A systematic review and meta-analysis of seven studies were conducted to evaluate aspirin's effects on major adverse cardiovascular events in diabetic patients.
Potential Biases
Potential biases include variability in trial designs and inconsistent reporting of outcomes.
Limitations
The analysis included only seven trials, which varied in design and patient populations, and there was moderate heterogeneity among the trials.
Participant Demographics
The studies included both men and women with diabetes, with some trials exclusively enrolling patients with type 1 or type 2 diabetes.
Statistical Information
Confidence Interval
0.82-1.00
Statistical Significance
p=0.945
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website